To help you manage effectively through the intricacies of 340B, Manatt Health has developed a 50-state survey on 340B, analyzing how states reimburse 340B covered entities and contract pharmacies for 340B drugs, and the steps states are taking to avoid duplicate discounts.
Based on a comprehensive review of statutory, regulatory and subregulatory guidance issued by state Medicaid agencies, as well as direct input from state officials, the survey provides a deep dive into 340B issues and approaches in each state, including:
- The mechanisms state Medicaid programs use to identify 340B-purchased drugs for exclusion from rebate requests to manufacturers
- How much state Medicaid programs reimburse covered entities and contract pharmacies for 340B-purchased drugs billed directly to the Medicaid program
- Whether the Medicaid program contains requirements for how much MCOs may reimburse covered entities and contract pharmacies for 340B-purchased drugs billed to MCOs
- How reimbursement for 340B-purchased drugs in any context differs from reimbursement for non-340B drugs
The survey includes an individual profile for each state, formatted in an easy-to-read chart. With wide variations among states, this is a critical tool for gaining a full understanding of 340B practices and requirements across the country—in one complete resource.
Click here to access a free infographic sharing key findings.
For more information on the survey, click here to read our complete press release.